黑色素瘤效用值估计的系统综述与Meta分析
该研究通过系统综述与Meta分析,汇总了黑色素瘤患者基于效用的健康相关生活质量估计值。共纳入33项研究、213个效用值,按分期及治疗阶段报告均值,供经济学评价使用。
核心结论
- 提供了稳健的、基于证据的黑色素瘤健康状态效用估计值,可用于新治疗的经济学评价。
研究设计与样本
- 系统综述、Meta分析与Meta回归,纳入33项研究报告的213个效用值。
临床怎么用
- 临床经济学评价可参考分期及治疗阶段的效用值进行成本-效用分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health-related quality of life (HRQOL) in melanoma is affected by cancer stage. Previous studies have reported limited data on utility-based HRQOL. OBJECTIVES: To determine pooled estimates of utility-based HRQOL (utilities) for people with American Joint Cancer Committee stage I/II, III or IV melanoma for use in economic evaluations. METHODS: We performed a systematic review, meta-analysis and metaregression of utilities for patients with melanoma. HRQOL scores reported with the QLQ-C30, SF-36, SF-12, FACT-G and FACT-M instruments were converted to utilities using published mapping algorithms. Meta-analysis was used to calculate mean utilities. Metaregression was used to examine the effects of baseline patient and study characteristics. RESULTS: We identified 33 studies reporting 213 utilities. From meta-analyses, the mean utility for stage I/II melanoma was 0·97 [95% confidence interval (CI) 0·90-0·98]; for stage III melanoma it was 0·77 (95% CI 0·70-0·83); for stage III/IV 0·76 (95% CI 0·76-0·77); and for stage IV melanoma 0·76 (95% CI 0·71-0·81). The difference in utility between stage III and stage IV was not statistically significant (P = 0·52). For patients with stage I/II, the utility estimate at the time of surgery was 0·77 (95% CI 0·75-0·79), and at 3-12 months postsurgery it was 0·85 (95% CI 0·84-0·86). Utility estimates for patients with stage IV melanoma were 0·65 (95% CI 0·62-0·69) during the first 3 months of treatment and 0·83 (95% CI 0·81-0·86) at 4-12 months on treatment. For patients with stage IV melanoma treated with chemotherapy, the utility estimate was 0·52 (95% CI 0·51-0·52), while for those treated with targeted therapy it was 0·83 (95% CI 0·82-0·85). CONCLUSIONS: These robust, evidence-based estimates of health state utility can be used in economic evaluations of new treatments for patients with early-stage or advanced-stage melanoma.
引用
- Tran AD, Fogarty G, Nowak AK, et al. A systematic review and meta-analysis of utility estimates in melanoma. Br J Dermatol. 2018. PMID: 29077983. doi:10.1111/bjd.16098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。